Clinical Trial Update: Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) [Phase 3]

View source ↗

Summary

Open-label extension of romiplostim in patients with immune thrombocytopenia (Idiopathic Thrombocytopenic Purpura) in a Phase 3 study; the trial completed and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Nplate (romiplostim)

Snippet

Sponsor: Amgen | Conditions: Thrombocytopenia, Idiopathic Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED | Results posted: 2011-04-06